Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease

Next Previous
Trial Profile

A Randomised, Placebo-controlled, Multicentre Phase IIb Study Evaluating the Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pirepemat (Primary)
  • Indications Dementia; Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms React-PD
  • Sponsors Integrative Research Laboratories

    • Most Recent Events

    • 27 Feb 2024 According to a IRLAB Therapeutics media release, abstract from this study has been accepted and will be presented at the scientific conference AD/PD™ 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal, on March 5-9, 2024.
    • 12 Dec 2023 According to a IRLAB media release, The study is active at 38 study sites across France, Germany, Poland, the Netherlands, Spain, and Sweden and it will identify the optimal dose for Phase III.
    • 17 Jul 2023 According to an IRLAB media release, company announced that the independent Data and Safety Monitoring Board (DSMB), after review (from the initial 25 patients participating in the study) of safety and the integrity of data unanimously recommends that the Phase IIb study continues.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top